Predicting flares in patients with stable systemic lupus erythematosus. 2019

Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
Division of Rheumatology, Department of Medicine, National University Hospital of Singapore, Level 10, NUHS Tower Block, 1E Kent Ridge Road, 119228, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: Jiacai_cho@nuhs.edu.sg.

Data on flares in Asian patients with systemic lupus erythematosus (SLE) are scarce. Here, we aim to identify the baseline predictors of flares in a cohort of Southeast Asian patients with SLE. Consecutive adult patients with prevalent SLE according to the 1997 ACR or 2012 SLICC criteria were enrolled and followed three-monthly. Clinical and laboratory data were collected at every visit using a standardised protocol. Flares were defined using the SELENA-SLEDAI Flare Index (SFI). Baseline predictors of flare in patients with stable disease (SLE Disease Activity Index-2K (SLEDAI-2K) of ≤ 4) were determined using Cox proportional hazards. Of the 210 patients recruited, 148 (70.5%) were Chinese. The median (IQR) SLEDAI-2K at entry was 2 (0-4) and the median (IQR) disease duration was 10 (4.4-16.4) years. At baseline, 152 (72.4%) patients had stable disease. After a median (IQR) follow-up of 31.5 (24.1-36.3) months, 109 (51.9%) flared. Stable patients who flared tended to be in the lowest tertile of age (HR 3.08, 95% CI 1.72-5.48, p < 0.01), had thrombocytopenia (HR 5.01, 95% CI 1.32-18.99, p = 0.02), hypocomplementemia (HR 3.35, 95% CI 1.54-7.30, p < 0.01) and had the highest baseline prednisolone doses (HR 2.39, 95% CI 1.28-4.46, p = 0.01). Conversely, patients in the lowest tertile of disease duration tended not to flare (HR 0.41, 95% CI 0.21-0.80, p = 0.01). Flares are common in Asian SLE patients with initial stable disease. Close monitoring is needed for patients who are younger, with longer disease duration, thrombocytopenia, hypocomplementemia, or who required a higher baseline prednisolone dose.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D012846 Singapore Country of islands in Southeastern Asia, islands between Malaysia and Indonesia. The capital is Singapore.

Related Publications

Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
July 2021, Rheumatology (Oxford, England),
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
April 2017, Rheumatology (Oxford, England),
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
December 2014, Rheumatology (Oxford, England),
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
June 2007, The Journal of rheumatology,
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
February 1997, Rheumatic diseases clinics of North America,
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
February 2015, Lupus,
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
June 2023, The Journal of rheumatology,
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
June 2018, Annals of the rheumatic diseases,
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
January 2003, Psychotherapy and psychosomatics,
Jiacai Cho, and Manjari Lahiri, and Lay Kheng Teoh, and Preeti Dhanasekaran, and Peter P Cheung, and Aisha Lateef
August 1996, Internal medicine (Tokyo, Japan),
Copied contents to your clipboard!